Assignee
SQUIBB & SONS LLC
US·35 granted patents·21 pending applications·954 citations·filing 2007–2025
Top patents by PatentIndex Score
56 records- 0199US10441655B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2016·Granted Oct 15, 2019·25 cites·22 claims
- 0299US9580507B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2016·Granted Feb 28, 2017·129 cites·30 claims
- 0399US9492539B2Monoclonal antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·119 cites·65 claims
- 0499US9492540B2Methods for treating cancer using anti-PD-1 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·139 cites·79 claims
- 0599US9387247B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Jul 12, 2016·124 cites·45 claims
- 0699US9358289B2Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Jun 7, 2016·137 cites·49 claims
- 0799US9273135B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Mar 1, 2016·109 cites·30 claims
- 0898US11001630B2Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted May 11, 2021·10 cites·20 claims
- 0998US10988536B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted Apr 27, 2021·10 cites·20 claims
- 1098US10344089B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2017·Granted Jul 9, 2019·25 cites·20 claims
- 1198US9580505B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·37 cites·41 claims
- 1297US11530267B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Dec 20, 2022·2 cites·21 claims
- 1397US11236165B2Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1497US11236163B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1597US11236164B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1696US11512130B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Nov 29, 2022·2 cites·22 claims
- 1796US10988535B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Granted Apr 27, 2021·10 cites·20 claims
- 1893US9631025B2Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodiesSQUIBB & SONS LLC·Filed 2015·Granted Apr 25, 2017·11 cites·12 claims
- 1992US2026028416A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2025·Application pending·0 cites
- 2091US9296822B2Human monoclonal antibodies to O8ESQUIBB & SONS LLC·Filed 2013·Granted Mar 29, 2016·15 cites·26 claims
- 2191US9138475B2Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodiesSQUIBB & SONS LLC·Filed 2013·Granted Sep 22, 2015·12 cites·16 claims
- 2289US9580467B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofSQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·5 cites·1 claims
- 2387US11072664B2Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2019·Granted Jul 27, 2021·3 cites·20 claims
- 2486US9499632B2Human antibodies that bind CD22 and uses thereofSQUIBB & SONS LLC·Filed 2013·Granted Nov 22, 2016·8 cites·42 claims
- 2586US2023322919A1Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses ThereofSQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 2686US2023272079A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2023·Application pending·0 cites
- 2785US11292814B2Cation exchange chromatography methodsSQUIBB & SONS LLC·Filed 2018·Granted Apr 5, 2022·2 cites·13 claims
- 2884US10448622B2Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2016·Granted Oct 22, 2019·1 cites·10 claims
- 2983US10385133B2Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2016·Granted Aug 20, 2019·2 cites·16 claims
- 3082US2023061544A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 3182US2022403046A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 3280US9226974B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofSQUIBB & SONS LLC·Filed 2014·Granted Jan 5, 2016·2 cites·8 claims
- 3380US2025154254A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2025·Application pending·0 cites
- 3479US2020138945A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3577US2021395375A1Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2021·Application pending·0 cites
- 3676US12157757B2Cation exchange chromatography methodsSQUIBB & SONS LLC·Filed 2022·Granted Dec 3, 2024·0 cites·12 claims
- 3775US2020236915A1Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3874US2021298277A1Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2021·Application pending·0 cites
- 3974US2020231671A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4073US9994633B2IP-10 antibodies and their usesSQUIBB & SONS LLC·Filed 2014·Granted Jun 12, 2018·1 cites·4 claims
- 4173US9988453B2Human monoclonal antibodies to O8ESQUIBB & SONS LLC·Filed 2016·Granted Jun 5, 2018·1 cites·16 claims
- 4271US2019119384A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2018·Application pending·0 cites
- 4371US2020062848A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4469US9217033B2Monoclonal antibodies against Glypican-3SQUIBB & SONS LLC·Filed 2014·Granted Dec 22, 2015·1 cites·9 claims
- 4568US2019315881A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4664US2017158767A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 4763US2016257753A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2016·Application pending·0 cites
- 4862US2017369568A1Interferon alpha antibodies and their usesSQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 4962US2017190785A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 5059US11312777B2Human monoclonal antibodies that bind CXCR4 and uses thereofSQUIBB & SONS LLC·Filed 2018·Granted Apr 26, 2022·0 cites·24 claims
Showing the top 50 of 56 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →